Upload folder using huggingface_hub
Browse files- brands.csv +30 -30
- combinations.csv +0 -0
- drugs.csv +16 -16
- formulations.csv +36 -36
- hospital_types.csv +4 -4
- indications.csv +8 -8
- treatment_phases.csv +54 -54
brands.csv
CHANGED
@@ -1,30 +1,30 @@
|
|
1 |
-
|
2 |
-
|
3 |
-
|
4 |
-
|
5 |
-
|
6 |
-
|
7 |
-
|
8 |
-
|
9 |
-
|
10 |
-
|
11 |
-
|
12 |
-
|
13 |
-
|
14 |
-
|
15 |
-
|
16 |
-
|
17 |
-
|
18 |
-
|
19 |
-
|
20 |
-
|
21 |
-
|
22 |
-
|
23 |
-
|
24 |
-
|
25 |
-
|
26 |
-
|
27 |
-
|
28 |
-
|
29 |
-
|
30 |
-
|
|
|
1 |
+
brands
|
2 |
+
Abrilada
|
3 |
+
Actemra
|
4 |
+
Actemra ACTPen
|
5 |
+
Actemra Subcutaneous Injection
|
6 |
+
Adalicip
|
7 |
+
Amgevita
|
8 |
+
Brenzys
|
9 |
+
Cimzia
|
10 |
+
Cosentyx
|
11 |
+
Enbrel
|
12 |
+
Hadlima
|
13 |
+
Humira
|
14 |
+
Hyrimoz
|
15 |
+
Idacio
|
16 |
+
Inflectra
|
17 |
+
Olumiant
|
18 |
+
Orencia
|
19 |
+
Orencia ClickJect
|
20 |
+
Remicade
|
21 |
+
Remsima SC
|
22 |
+
Renflexis
|
23 |
+
Rinvoq
|
24 |
+
Saphnelo
|
25 |
+
Simponi
|
26 |
+
Stelara
|
27 |
+
Taltz
|
28 |
+
Tremfya
|
29 |
+
Xeljanz
|
30 |
+
Yuflyma
|
combinations.csv
CHANGED
The diff for this file is too large to render.
See raw diff
|
|
drugs.csv
CHANGED
@@ -1,16 +1,16 @@
|
|
1 |
-
|
2 |
-
|
3 |
-
|
4 |
-
|
5 |
-
|
6 |
-
|
7 |
-
|
8 |
-
|
9 |
-
|
10 |
-
|
11 |
-
|
12 |
-
|
13 |
-
|
14 |
-
|
15 |
-
|
16 |
-
|
|
|
1 |
+
drugs
|
2 |
+
abatacept
|
3 |
+
adalimumab
|
4 |
+
anifrolumab
|
5 |
+
baricitinib
|
6 |
+
certolizumab pegol
|
7 |
+
etanercept
|
8 |
+
golimumab
|
9 |
+
guselkumab
|
10 |
+
infliximab
|
11 |
+
ixekizumab
|
12 |
+
secukinumab
|
13 |
+
tocilizumab
|
14 |
+
tofacitinib
|
15 |
+
upadacitinib
|
16 |
+
ustekinumab
|
formulations.csv
CHANGED
@@ -1,36 +1,36 @@
|
|
1 |
-
|
2 |
-
|
3 |
-
|
4 |
-
|
5 |
-
|
6 |
-
|
7 |
-
|
8 |
-
|
9 |
-
|
10 |
-
|
11 |
-
|
12 |
-
|
13 |
-
|
14 |
-
|
15 |
-
|
16 |
-
|
17 |
-
|
18 |
-
|
19 |
-
|
20 |
-
|
21 |
-
|
22 |
-
|
23 |
-
|
24 |
-
|
25 |
-
|
26 |
-
|
27 |
-
|
28 |
-
|
29 |
-
|
30 |
-
|
31 |
-
|
32 |
-
|
33 |
-
|
34 |
-
|
35 |
-
|
36 |
-
|
|
|
1 |
+
formulations
|
2 |
+
Concentrate for injection 200 mg in 10 mL
|
3 |
+
Concentrate for injection 400 mg in 20 mL
|
4 |
+
Concentrate for injection 80 mg in 4 mL
|
5 |
+
Injection 100 mg in 1 mL single use pre-filled pen
|
6 |
+
Injection 100 mg in 1 mL single use pre-filled syringe
|
7 |
+
Injection 125 mg in 1 mL single dose autoinjector
|
8 |
+
Injection 125 mg in 1 mL single dose pre-filled syringe
|
9 |
+
Injection 150 mg in 1 mL pre-filled pen
|
10 |
+
Injection 162 mg in 0.9 mL single use pre-filled pen
|
11 |
+
Injection 162 mg in 0.9 mL single use pre-filled syringe
|
12 |
+
Injection 20 mg in 0.2 mL pre-filled syringe
|
13 |
+
Injection 20 mg in 0.4 mL pre-filled syringe
|
14 |
+
Injection 200 mg in 1 mL single use pre-filled syringe
|
15 |
+
Injection 40 mg in 0.4 mL pre-filled pen
|
16 |
+
Injection 40 mg in 0.4 mL pre-filled syringe
|
17 |
+
Injection 40 mg in 0.8 mL pre-filled pen
|
18 |
+
Injection 40 mg in 0.8 mL pre-filled syringe
|
19 |
+
Injection 45 mg in 0.5 mL
|
20 |
+
Injection 50 mg in 0.5 mL single use pre-filled pen
|
21 |
+
Injection 50 mg in 0.5 mL single use pre-filled syringe
|
22 |
+
"Injection 50 mg in 1 mL single use auto-injector, 4"
|
23 |
+
Injection 80 mg in 1 mL single dose pre-filled pen
|
24 |
+
Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL
|
25 |
+
"Injections 50 mg in 1 mL single use pre-filled syringes, 4"
|
26 |
+
"Oral solution 1 mg per mL, 240 mL"
|
27 |
+
Powder for I.V. infusion 100 mg
|
28 |
+
Powder for I.V. infusion 250 mg
|
29 |
+
Solution concentrate for I.V. infusion 300 mg in 2 mL
|
30 |
+
Solution for injection 120 mg in 1 mL pre-filled pen
|
31 |
+
Solution for injection 120 mg in 1 mL pre-filled syringe
|
32 |
+
Solution for injection 200 mg in 1 mL pre-filled pen
|
33 |
+
Tablet 15 mg
|
34 |
+
Tablet 2 mg
|
35 |
+
Tablet 4 mg
|
36 |
+
Tablet 5 mg
|
hospital_types.csv
CHANGED
@@ -1,4 +1,4 @@
|
|
1 |
-
|
2 |
-
|
3 |
-
|
4 |
-
|
|
|
1 |
+
hospital_types
|
2 |
+
Any
|
3 |
+
Private
|
4 |
+
Public
|
indications.csv
CHANGED
@@ -1,8 +1,8 @@
|
|
1 |
-
|
2 |
-
|
3 |
-
|
4 |
-
|
5 |
-
|
6 |
-
|
7 |
-
|
8 |
-
|
|
|
1 |
+
indications
|
2 |
+
ankylosing spondylitis
|
3 |
+
giant cell arteritis
|
4 |
+
juvenile idiopathic arthritis
|
5 |
+
non-radiographic axial spondyloarthritis
|
6 |
+
psoriatic arthritis
|
7 |
+
rheumatoid arthritis
|
8 |
+
systemic lupus erythematosus
|
treatment_phases.csv
CHANGED
@@ -1,54 +1,54 @@
|
|
1 |
-
|
2 |
-
|
3 |
-
|
4 |
-
|
5 |
-
|
6 |
-
|
7 |
-
|
8 |
-
|
9 |
-
|
10 |
-
|
11 |
-
|
12 |
-
|
13 |
-
|
14 |
-
|
15 |
-
|
16 |
-
|
17 |
-
|
18 |
-
|
19 |
-
|
20 |
-
|
21 |
-
|
22 |
-
|
23 |
-
|
24 |
-
|
25 |
-
|
26 |
-
|
27 |
-
|
28 |
-
|
29 |
-
|
30 |
-
|
31 |
-
|
32 |
-
|
33 |
-
|
34 |
-
|
35 |
-
|
36 |
-
|
37 |
-
|
38 |
-
|
39 |
-
|
40 |
-
|
41 |
-
|
42 |
-
|
43 |
-
|
44 |
-
|
45 |
-
|
46 |
-
|
47 |
-
|
48 |
-
|
49 |
-
|
50 |
-
|
51 |
-
|
52 |
-
|
53 |
-
|
54 |
-
|
|
|
1 |
+
treatment_phases
|
2 |
+
Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription
|
3 |
+
Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months)
|
4 |
+
Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine
|
5 |
+
"Balance of supply for Initial treatment, Continuing treatment - subcutaneous form"
|
6 |
+
Continuing Treatment - balance of supply
|
7 |
+
Continuing or recommencement of treatment (within 12 months of a treatment break)
|
8 |
+
Continuing treatment
|
9 |
+
Continuing treatment - balance of supply
|
10 |
+
Continuing treatment in a patient weighing at least 30 kg
|
11 |
+
Continuing treatment in a patient weighing less than 30 kg
|
12 |
+
Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form
|
13 |
+
First Continuing treatment
|
14 |
+
First Continuing treatment - balance of supply
|
15 |
+
First continuing treatment
|
16 |
+
First continuing treatment - balance of supply
|
17 |
+
"Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply"
|
18 |
+
"Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply"
|
19 |
+
"Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply"
|
20 |
+
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
|
21 |
+
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
|
22 |
+
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
|
23 |
+
Initial treatment
|
24 |
+
Initial treatment - Initial 1 (New patient)
|
25 |
+
Initial treatment - Initial 1 (new patient weighing at least 30 kg)
|
26 |
+
Initial treatment - Initial 1 (new patient weighing less than 30 kg)
|
27 |
+
Initial treatment - Initial 1 (new patient)
|
28 |
+
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
|
29 |
+
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
|
30 |
+
"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply"
|
31 |
+
"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply"
|
32 |
+
Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years)
|
33 |
+
Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years)
|
34 |
+
Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years)
|
35 |
+
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
|
36 |
+
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
|
37 |
+
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
|
38 |
+
Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)
|
39 |
+
Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)
|
40 |
+
Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg)
|
41 |
+
Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg)
|
42 |
+
Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)
|
43 |
+
Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)
|
44 |
+
Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg)
|
45 |
+
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
|
46 |
+
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
|
47 |
+
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
|
48 |
+
Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg)
|
49 |
+
Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months)
|
50 |
+
Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
|
51 |
+
Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)
|
52 |
+
Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made
|
53 |
+
Subsequent continuing treatment
|
54 |
+
Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
|